| 000 | 01890 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250515201956.0 | ||
| 264 | 0 | _c20100330 | |
| 008 | 201003s 0 0 eng d | ||
| 022 | _a1865-3774 | ||
| 024 | 7 |
_a10.1007/s12185-009-0461-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZhai, Linzhu | |
| 245 | 0 | 0 |
_aLong-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin's lymphoma: single center, 15-year experience. _h[electronic resource] |
| 260 |
_bInternational journal of hematology _cJan 2010 |
||
| 300 |
_a78-86 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, Non-Hodgkin _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPrednisone _xadministration & dosage |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVincristine _xadministration & dosage |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aGuo, Chengcheng | |
| 700 | 1 | _aCao, Yabing | |
| 700 | 1 | _aXiao, Jian | |
| 700 | 1 | _aFu, Xiaohong | |
| 700 | 1 | _aHuang, Jiajia | |
| 700 | 1 | _aHuang, Huiqiang | |
| 700 | 1 | _aGuan, Zhongzhen | |
| 700 | 1 | _aLin, Tongyu | |
| 773 | 0 |
_tInternational journal of hematology _gvol. 91 _gno. 1 _gp. 78-86 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s12185-009-0461-8 _zAvailable from publisher's website |
| 999 |
_c19413831 _d19413831 |
||